Compare Etsy Inc (ETSY) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Novavax Inc — how do they compare? Etsy Inc trades at $76.71 (market cap $6.90B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Etsy Inc is far larger — about 3.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Etsy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Novavax Inc for 59 Days on average.
| ETSY | NVAX | |
|---|---|---|
Market Cap | $6.90B | $1.82B |
Volume | 2,923,867 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $12.56 |
52-Week Low | $44.05 | $6.22 |
Typical Hold Time | 67 Days | 59 Days |
Enterprise Value | $8.85B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $75.14, up 5.11% today, showing strong momentum with three consecutive earnings beats. The stock maintains a bullish technical outlook with support at $73 and resistance at $76. Fundamentally, revenue growth has been steady at $2.9B annually, though net margins compressed to 5.65% in 2025. Recent news highlights AI integration and payment partnerships as growth catalysts.
The outlook remains positive with a $85.94 analyst price target suggesting 14% upside. Key risks include high debt levels and competitive pressures. Wall Street sentiment is bullish (53% buy ratings), but investors should monitor margin trends and execution of AI initiatives for sustained growth.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
